Loading clinical trials...
Loading clinical trials...
The Effect of CTLA-4/PD-L1 Blockade Following Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC Using Durvalumab (MEDI4736) and Tremelimumab
Conditions
Interventions
Durvalumab
Tremelimumab
Locations
1
United States
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Start Date
October 2, 2019
Primary Completion Date
August 20, 2024
Completion Date
August 20, 2024
Last Updated
August 17, 2025
NCT06066138
NCT06811116
NCT07485114
NCT06345508
NCT04380545
NCT07291076
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions